Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fallopian Tube Neoplasms × sapanisertib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Endometrial Neoplasms 2 Carcinoma, Transitional Cell 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Somatostatinoma 1 Recurrent Lung Squamous Cell Carcinoma 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Metastatic Castration-Resistant Prostate Cancer 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Genital Diseases 1 Fallopian Tube Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Endometrioid 1 Burkitt Lymphoma 1

Interventions

Carboplatin 46 Paclitaxel 41 Bevacizumab 30 Gemcitabine 15 pembrolizumab 14 Taxes 11 Cisplatin 11 olaparib 10 Immunoglobulin G 10 Disulfides 10 Topotecan 9 Cyclophosphamide 7 niraparib 6 Specimen Handling 6 Biopsy 6 Nivolumab 5 Drug Therapy 5 Cytoreduction Surgical Procedures 5 oregovomab 4 mirvetuximab soravtansine 4 liposomal doxorubicin 4 Neoadjuvant Therapy 4 Magnetic Resonance Spectroscopy 4 Letrozole 4 Hyperthermic Intraperitoneal Chemotherapy 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Albumin-Bound Paclitaxel 4 130-nm albumin-bound paclitaxel 4 tremelimumab 3 sargramostim 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03648489 2024-09-20

DICE

Imperial College London

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡